Home Neoplasma 2015 Neoplasma Vol.62, No.2, p.191-198, 2015

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.62, No.2, p.191-198, 2015

Title: MicroRNA 363 mediated positive regulation of c-myc translation affect prostate cancer development and progress
Author: Y. CHEN, X. LU, B. WU, Y. SU, J. LI, H. WANG

Abstract: Prostate cancer (CaP) is the sixth most significant cancer killer of men in China. In this study, the potential role of micro-363 (miR-363) in CaP development and progression was investigated. Pri-miR-363 or anti-miR-363 was transfected into the CaP cells line PC-3 cells. Cell proliferation, transformation property, and epithelial-to-mesenchymal transition (EMT) were evaluated by MTT, clonogenic assay, colony formation in soft agar and western blotting, respectively. The expression and involvement of c-myc, a downstream target of miR-363 were also determined. The results showed that endogenous expression of miR-363 was significantly increased in CaP cells compared with normal prostate cells. High expression of miR-363 in PC-3 cells through transfection induces cell proliferation and positively regulates cell transformation property as well as promotes EMT of PC-3 cells. Through knockdown of c-myc, the results also showed that c-myc was involved in the regulation of biological function of PC-3 cells by miR-363. Taken together, this study adds support to the potential role of miR-363 in the diagnosis and treatment of CaP.

Keywords: Prostate cancer, transformation property, proliferation, micro-363, epithelial-to-mesenchymal transition
Published online: 14-Jan-2015
Year: 2015, Volume: 62, Issue: 2 Page From: 191, Page To: 198
doi:10.4149/neo_2015_024


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.